Psoriatic Arthritis Patients Have a New Option

| Samantha Koons

One in three patients with psoriasis will go on to develop psoriatic arthritis (PsA). For some of these patients, a new treatment option is on the horizon. On July 14, 2020, the U.S. Food and Drug Administration approved the use of Tremfya® (guselkumab) for use in adult patients with active psoriatic arthritis.

“PsA occurs in 30 percent of patients with psoriasis and is the most common comorbidity for these patients,” says Dr. Alice Gottlieb, M.D., Ph.D., Medical Director, Mount Sinai Beth Israel Dermatology and Clinical Professor, Department of Dermatology at Icahn School of Medicine at Mount Sinai, New York. “Every patient with psoriasis should be evaluated for PsA at every visit with their dermatologist.”

“The effect of PsA on patients’ lives can be significant,” says Dr. Atul Deodhar, M.D., M.R.C.P., Professor of Medicine, Division of Arthritis and Rheumatic Diseases, School of Medicine at Oregon Health and Science University. PsA can affect any joint and function can be very limited. A patient’s mental health can be affected, including having a significant risk for depression. “For patients with psoriasis, having psoriatic arthritis can lower their quality of life.”

Tremfya®, manufactured by Janssen, is proposed to work by binding to the p19 subunit of IL-23, thereby inhibiting its reaction with the IL-23 receptor. This action stops the release of proinflammatory cytokines and chemokines.

“PsA has 5 different domains, including skin, joint, nail, axial spine, and enthesis. Data resulting from studies on guselkumab (Tremfya) demonstrate that it may be effective on all domains, including the axial spine,” says Dr. Deodhar. “There is a need for new treatment options, especially ones with better safety and efficacy. This new treatment adds another option for patients who haven’t responded to other previous treatments.”

Tremfya® was previously approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Even during a pandemic, your voice matters.
a young family with psoriasis or psoriatic disease enjoying beach together
This August, we take action together, in support of our community.
Zack Harrison is turning 9 this year, and he’s already a vocal member of our...
A new topical treatment option is now available to patients.
When COVID-19 struck and society shut down, digital advocacy grew up – fast.
FDA Approves Tremfya® for the Treatment of Psoriatic Arthritis
research into new drug treatments in pipeline for psoriasis
More biologics, an oral medication and a topical draw interest from top...